New User:

-or-
Username:
Password:
Forgot your password?
News Breaks
08:04 EDTAVII
theflyonthewall.com: AVI BioPharma present update on on AVI-4658
AVI BioPharma announced presentations on the company's exon skipping therapy for Duchenne muscular dystrophy at the TREAT-NMD / NIH International Conference taking place Nov. 17-19 in Brussels, Belgium. At the conference, data from the company's clinical and preclinical programs were presented. An update on the company's ongoing systemic Phase 1b/2 trial of AVI-4658 was provided by Professor Francesco Muntoni, of the MDEX consortium in the UK, during an oral presentation and also summarized in a poster presentation. The most recent data from the ongoing Phase 1b/2 trial at two MDEX sites in the UK demonstrate that AVI-4658 was well tolerated by DMD patients in a dose escalation study that is now up to the sixth and final cohort. The maximum cumulative dose administered to date is 3132 mg and the maximum single dose is 900 mg with no adverse safety signals, in either case. :theflyonthewall.com



News For AVII From The Last 14 Days
Check below for free stories on AVII the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2010
08:08 EDTAVII
theflyonthewall.com: AVI BioPharma receives European Orphan Drug Designation for AVI-5038

Subscribe for More Information
:theflyonthewall.com

February 4, 2010
08:03 EDTAVII
theflyonthewall.com: AVI BioPharma announces study/findings on of AVI-4658

Subscribe for More Information
:theflyonthewall.com